StockData
Glucotrack, Inc. logo

Glucotrack, Inc. (GCTK) stock

GCTKOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.68−0.04 (-5.56%)

Close on Oct 19, 2026Market cap $3.43MP/E 0.0Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$3.43M
P/E ratio
0.0
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
-447.15%

Fundamentals

Net income
-$15.95M
EPS, diluted
$31.22
Free cash flow
-$15.34M
Book value per share
-$0.35
Diluted shares
5M

Trading

Previous close
$0.72
Open
$0.74
Day's range
$0.68 – $0.74
Volume
102,790
Average volume (20 days)
4,343,118

Market cap history

Month-end market cap since 2013, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodGCTKS&P 500DifferenceGCTK per yearS&P 500 per year
1 month-72.3%+0.6%−72.9 pts
3 months-90.7%+3.4%−94.1 pts
Year to date-98.8%+13.3%−112.1 pts
1 year-99.3%+16.6%−115.9 pts
3 years-100.0%+86.4%−186.4 pts-96.8%+23.1%
5 years-100.0%+81.9%−181.9 pts-93.2%+12.7%
10 years-100.0%+318.9%−418.9 pts-78.3%+15.4%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$15.40M

Net income

-$15.95M

EPS, diluted

–

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Glucotrack filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Glucotrack

Surgical & Medical Instruments & Apparatus

Glucotrack, Inc. is a medical device company focused on developing an implantable continuous blood glucose monitoring system, the Glucotrack CBGM. Designed for individuals with Type 1 diabetes as well as individuals with Type 2 diabetes who use insulin or are at risk for hypoglycemia, the system requires no additional wearable component. The device uses an intravascular design featuring a subcutaneously implanted unit connected to a lead inserted directly into a blood vessel to provide continuous blood glucose measurements. The company also investigates glucose sensing in the epidural space for patients considering spinal cord stimulation.

Company profile, executives and history

Glucotrack stock: common questions

What is Glucotrack's stock price?

GCTK closed at $0.68 on Oct 19, 2026, down 5.56% on the day.

What is Glucotrack's market cap?

Glucotrack was worth $3.43M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is GCTK's P/E ratio?

GCTK trades at 0.0 times earnings, based on diluted earnings per share of $31.22 over fiscal 2025.

Does Glucotrack pay a dividend?

No. Glucotrack has not paid a cash dividend over the last twelve months.

How has GCTK stock performed over the past year?

Including dividends, GCTK returned -99.3% over the past year, against +16.6% for the S&P 500.

Who are Glucotrack's competitors?

Companies most similar to Glucotrack by business, industry and size include MODD, DXCM, PODD, PFSA, BBNX.

See a number that looks wrong?